Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans

Jurcevic, S., Juif, P.E., Hamid, C., Greenlaw, R., D'Ambrosio, D. and Dingemanse, J. 2016. Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy. 11, pp. 123-131. https://doi.org/10.2147/DDDT.S120399

TitleEffects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans
AuthorsJurcevic, S.
Juif, P.E.
Hamid, C.
Greenlaw, R.
D'Ambrosio, D.
Dingemanse, J.
Abstract

This study investigated the effects of ponesimod, a selective SIP1 receptor modulator, on T lymphocyte subsets in 16 healthy subjects. Lymphocyte subset proportions and absolute numbers were determined at baseline and on Day 10, after once-daily administration of ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days) or placebo (ratio 3: 1). The overall change from baseline in lymphocyte count was -1,292 +/- 340x10(6) cells/L and 275 +/- 486x10(6) cells/L in ponesimod- and placebo-treated subjects, respectively. This included a decrease in both T and B lymphocytes following ponesimod treatment. A decrease in naive CD4(+) T cells (CD45RA(+)CCR7(+)) from baseline was observed only after ponesimod treatment (-113 +/- 98x10(6) cells/L, placebo: 0 +/- 18x10(6) cells/L). The number of T-cytotoxic (CD3(+)CD8(+)) and T-helper (CD3(+)CD4(+)) cells was significantly altered following ponesimod treatment compared with placebo. Furthermore, ponesimod treatment resulted in marked decreases in CD4(+) T-central memory (CD45RA(-)CCR7(+)) cells (-437 +/- 164x10(6) cells/L) and CD4(+) T-effector memory (CD45RA(-)CCR7(-)) cells (-131 +/- 57x10(6) cells/L). In addition, ponesimod treatment led to a decrease of -228 +/- 90x10(6) cells/L of gut-homing T cells (CLA(-)integrin beta 7(+)). In contrast, when compared with placebo, CD8(+) T-effector memory and natural killer (NK) cells were not significantly reduced following multiple-dose administration of ponesimod. In summary, ponesimod treatment led to a marked reduction in overall T and B cells. Further investigations revealed that the number of CD4(+) cells was dramatically reduced, whereas CD8(+) and NK cells were less affected, allowing the body to preserve critical viral-clearing functions.

Keywordsponesimod; multiple dose; SIP1 receptor; lymphocyte subsets; CD45RA/CCR7
JournalDrug Design, Development and Therapy
Journal citation11, pp. 123-131
ISSN1177-8881
Year2016
PublisherDove Medical Press Ltd.
Publisher's version
Digital Object Identifier (DOI)https://doi.org/10.2147/DDDT.S120399
Publication dates
Published in print2017
Published online28 Dec 2016
Published28 Dec 2016
LicenseCC BY-NC 3.0

Related outputs

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
Mortoglou, M., Miralles, F., Arisan, E.D., Dart, A., Jurcevic, S., Lange, S. and Uysal Onganer, P. 2022. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 23 (3) 1275. https://doi.org/10.3390/ijms23031275

Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1)
Lee, M.H., Thomas, J.L., Liao, C.L., Jurcevic, S., Crnogorac-Jurcevic, T. and Lin, H.Y. 2018. Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1). Separation and Purification Technology. 192, pp. 213-219. https://doi.org/10.1016/j.seppur.2017.09.071

Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma
Jurcevic, S., Lee, M-H., Thomas, J.L., Liao, C-L., Crnogorac-Jurcevic, T. and Lin, H-Y. 2017. Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma. Microchimica Acta. 184 (6), p. 1773–1780. https://doi.org/10.1007/s00604-017-2169-4

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Simha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology. 57 (2), pp. 194-210. https://doi.org/10.1002/jcph.794

The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic, S., Humfrey, C., Uddin, M., Warrington, S., Larsson, B. and Keen, C. 2015. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. . 80 (6), pp. 1324-36. https://doi.org/10.1111/bcp.12724

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski, J.A., Zhou, C., Winters, K.J., Lachno, D.R., Howard, J., Payne, C.D., Mant, T., Jurcevic, S. and Frelinger, A.L. 2015. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 26 (5), pp. 474-479. https://doi.org/10.3109/09537104.2014.940887

FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells
Rani, A., Greenlaw, R., Runglall, M., Jurcevic, S. and John, S. 2014. FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. PLoS ONE. 9 (2), p. e90370. https://doi.org/10.1371/journal.pone.0090370

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Jakubowski, J.A., Zhou, C., Jurcevic, S., Winters, K.J., Lachno, D.R., Frelinger, A.L., Gupta, N., Howard, J., Payne, C.D. and Mant, T. 2014. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis Research. 133 (2), pp. 190-5. https://doi.org/10.1016/j.thromres.2013.12.008

Permalink - https://westminsterresearch.westminster.ac.uk/item/9z9qx/effects-of-multiple-dose-ponesimod-a-selective-sip1-receptor-modulator-on-lymphocyte-subsets-in-healthy-humans


Share this

Usage statistics

85 total views
117 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.